JP2019524687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524687A5 JP2019524687A5 JP2018568875A JP2018568875A JP2019524687A5 JP 2019524687 A5 JP2019524687 A5 JP 2019524687A5 JP 2018568875 A JP2018568875 A JP 2018568875A JP 2018568875 A JP2018568875 A JP 2018568875A JP 2019524687 A5 JP2019524687 A5 JP 2019524687A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- hiv
- drug
- antibody drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 19
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 18
- 230000003472 neutralizing effect Effects 0.000 claims 15
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 8
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 230000036436 anti-hiv Effects 0.000 claims 6
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 3
- 229940125644 antibody drug Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 150000001875 compounds Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Claims (21)
- 式(I):
Ab−L−D (I)
[式中:
Abは、HIVエンベロープ糖タンパク質に対する結合親和性を有する広域中和抗体を含んでなり;
Lは、前記広域中和抗体と共有結合したリンカー分子を含んでなり;および
Dは、前記リンカー分子と共有結合した1つ以上の薬物を含んでなり、前記1つ以上の薬物は前記HIVエンベロープ糖タンパク質と結合することができる]
の抗体薬物複合体。 - 前記広域中和抗体がCD4結合部位と結合する、請求項1に記載の抗体薬物複合体。
- 前記1つ以上の薬物が、付着阻害剤である、請求項1に記載の抗体薬物複合体。
- 式(I):
Ab−[L−Dn]x (I)
[式中:
Abは、広域中和抗HIV抗体を含んでなり;
Lは、前記広域中和抗HIV抗体と共有結合したリンカー分子を含んでなり;
Dは、前記リンカー分子Lと共有結合したHIV治療用化合物を含んでなる1つ以上の薬物を含んでなり、前記1つ以上の広域中和抗HIV抗体AbはHIVエンベロープ糖タンパク質と特異的に結合し、前記1つ以上の薬物DはHIVエンベロープ糖タンパク質と特異的に結合し;
nは、1〜4から選択され;および
xは、1〜12から選択される]
の抗体薬物複合体。 - 前記広域中和抗体Abが、gp160、gp120およびgp41からなる群から選択されるHIVエンベロープ糖タンパク質と結合する、請求項4に記載の抗体薬物複合体。
- 前記広域中和抗体Abが、gp120/gp41接合部分、CD4結合部位またはgp41膜貫通部位近傍(MPER)においてHIVエンベロープ糖タンパク質と結合する、請求項4に記載の抗体薬物複合体。
- 前記薬物Dが、gp160、gp120およびgp41からなる群から選択されるHIVエンベロープ糖タンパク質と特異的に結合する、請求項4に記載の抗体薬物複合体。
- 前記薬物Dが、付着阻害剤である、請求項4に記載の抗体薬物複合体。
- 前記薬物Dが、CD4と結合するペプチドである、請求項4に記載の抗体薬物複合体。
- 式(I):
Ab−[L−Dn]x (I)
[式中:
Abは、広域中和抗HIV抗体を含んでなり;
Lは、前記広域中和抗HIV抗体と共有結合したリンカー分子を含んでなり;
Dは、前記リンカー分子Lと共有結合したHIV治療用化合物を含んでなる1つ以上の薬物を含んでなり、前記1つ以上の広域中和抗HIV抗体AbはHIVエンベロープ糖タンパク質と特異的に結合し、前記1つ以上の薬物DはHIVエンベロープ糖タンパク質と特異的に結合し;
nは、1〜4から選択され;
xは、1〜12から選択され、抗体薬物複合体は、(1)前記広域中和抗体と共有結合している、第一リンカー分子Lと共有結合した第一薬物Dおよび(2)前記広域中和抗体と共有結合している、第二リンカー分子Lと共有結合した第二薬物Dを含んでなる]
の抗体薬物複合体。 - 前記2つの薬物が、gp120付着阻害剤、gp160付着阻害剤およびその組合せからなる群から選択される、請求項10に記載の抗体薬物複合体。
- 前記抗体薬物複合体中の薬物がペプチドまたはポリペプチドである、請求項1〜11に記載の抗体薬物複合体。
- 前記リンカーが、融合タンパク質をもたらす抗体重鎖の1つもしくは両方または抗体軽鎖の1つもしくは両方と、薬物ペプチドもしくは薬物ポリペプチドとを結合させるアミノ酸リンカーである、請求項12に記載の抗体薬物複合体。
- 前記薬物ペプチドまたは薬物ポリペプチドが、抗体の重鎖の1つまたは両方のC末端と融合する、請求項13に記載の抗体薬物複合体。
- 前記アミノ酸リンカーが0〜150アミノ酸長である、請求項12〜14のいずれか一項に記載の抗体薬物複合体。
- 前記アミノ酸リンカーが0〜50アミノ酸長である、請求項15に記載の抗体薬物複合体。
- 前記広域中和抗体Abが、2G12、2F5、3BC176、3BNC60、3BNC117、4E10、8ANC131、8ANC195、10E8、10−1074、12A12、35O22、b12、B2530、CH01−04、CH103、CH31、HJ16、M66.6、N6、N6−LS、NIH45−46、PG9、PG16、PGDM1400、PGT121、PGT128、PGT135、PGT141−PGT145、PGT151、PGV04、VRC01、VRC01−LS、VRC07、VRC07−523、VRC07−LSおよびZ13からなる群から選択される、請求項1〜16のいずれか一項に記載の抗体薬物複合体。
- 前記広域中和抗体が、4E10、10E8、2F5およびZ13e1からなる群から選択される、請求項17に記載の抗体薬物複合体。
- 請求項1〜18のいずれか一項に記載の抗体薬物複合体、および薬剤的に許容可能な賦形剤を含んでなる、医薬組成物。
- 1つ以上の追加のHIV治療薬を含んでなる、請求項19に記載の医薬組成物。
- 対象のHIV感染症の治療または予防に使用するための請求項1〜18のいずれか一項に記載の抗体薬物複合体、または請求項19もしくは20に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357410P | 2016-07-01 | 2016-07-01 | |
US62/357,410 | 2016-07-01 | ||
PCT/IB2017/053979 WO2018002902A1 (en) | 2016-07-01 | 2017-06-30 | Antibody-drug conjugates and therapeutic methods using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019524687A JP2019524687A (ja) | 2019-09-05 |
JP2019524687A5 true JP2019524687A5 (ja) | 2020-08-13 |
Family
ID=59399452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018568875A Withdrawn JP2019524687A (ja) | 2016-07-01 | 2017-06-30 | 抗体薬物複合体およびこれを用いた治療方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190328900A1 (ja) |
EP (1) | EP3478324A1 (ja) |
JP (1) | JP2019524687A (ja) |
TW (1) | TW201811376A (ja) |
WO (1) | WO2018002902A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112638426B (zh) * | 2018-09-21 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
JP2022519586A (ja) * | 2019-02-04 | 2022-03-24 | ゼネティック バイオサイエンシーズ インコーポレイテッド | 糖ポリシアル酸化治療用タンパク質を使用する方法 |
WO2021076965A1 (en) * | 2019-10-17 | 2021-04-22 | Minicircle, Inc. | Nucleic acids encoding hiv neutralizing antibodies and uses thereof |
WO2021116872A1 (en) * | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
WO2022125378A2 (en) * | 2020-12-07 | 2022-06-16 | Viiv Healthcare Company | Combination therapy |
CA3216175A1 (en) | 2021-04-05 | 2022-10-13 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
CN115590965B (zh) * | 2021-06-28 | 2024-06-28 | 前沿生物药业(南京)股份有限公司 | 用于治疗和/或预防hiv相关疾病的aptc偶联物及其应用 |
IL313306A (en) * | 2021-12-17 | 2024-08-01 | Viiv Healthcare Co | Combined treatments for HIV infections and their uses |
WO2023194501A1 (en) | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
CN117138104A (zh) * | 2023-09-18 | 2023-12-01 | 潍坊医学院附属医院 | 一种用于烧伤创面的抗氧化蛋白肽基纳米水凝胶 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
JPH11507632A (ja) | 1995-06-07 | 1999-07-06 | トリメリス,インコーポレーテッド | 併用療法を用いたhivおよび他のウイルス感染の治療 |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
HUP0400241A2 (hu) | 2001-03-19 | 2004-06-28 | Ono Pharmaceutical Co., Ltd. | Hatóanyagként triaza-spiro[5.5]undekán-származékokat tartalmazó gyógyszerkészítmények |
AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2008088806A1 (en) | 2007-01-16 | 2008-07-24 | Johns Hopkins University | Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
CA2687178C (en) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
EP2326349B1 (en) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
EP2549276B1 (en) | 2009-08-10 | 2015-02-25 | UCL Business PLC | Reversible covalent linkage of functional molecules |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
EP2480572B1 (en) | 2009-09-25 | 2019-01-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
WO2011046623A2 (en) | 2009-10-16 | 2011-04-21 | Duke University | Hiv-1 antibodies |
US8765920B2 (en) * | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
EP2528625B1 (en) | 2010-04-15 | 2013-07-10 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
ES2618380T3 (es) | 2010-09-24 | 2017-06-21 | International Aids Vaccine Initiative | Novedosos anticuerpos con amplio poder neutralizante de VIH-1 |
AU2011323354B2 (en) * | 2010-11-03 | 2014-07-31 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
EP2638072A4 (en) | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR HIV THERAPY |
WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
CA2837167A1 (en) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US20150158934A1 (en) | 2011-09-09 | 2015-06-11 | Ucl Business Plc | Broadly neutralizing vhh against hiv-1 |
ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
BR112014010823B1 (pt) | 2011-11-07 | 2021-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
WO2013086533A1 (en) | 2011-12-08 | 2013-06-13 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
EA035012B1 (ru) | 2012-10-18 | 2020-04-17 | Рокфеллер Юниверсити (Дзе) | Нейтрализующие анти-вич-антитела широкого спектра действия |
EP2911699B1 (en) | 2012-10-23 | 2017-11-15 | SynAffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
US9738688B2 (en) | 2012-11-05 | 2017-08-22 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
UY35418A (es) | 2013-03-15 | 2014-10-31 | Glaxosmithkline Biolog Sa | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
CN106102837B (zh) | 2013-12-02 | 2020-10-13 | 艾伦戴蒙德艾滋病研究中心 | 双特异性hiv-1-中和抗体 |
US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
-
2017
- 2017-06-30 WO PCT/IB2017/053979 patent/WO2018002902A1/en unknown
- 2017-06-30 JP JP2018568875A patent/JP2019524687A/ja not_active Withdrawn
- 2017-06-30 TW TW106122147A patent/TW201811376A/zh unknown
- 2017-06-30 EP EP17743394.3A patent/EP3478324A1/en not_active Withdrawn
- 2017-06-30 US US16/308,862 patent/US20190328900A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019524687A5 (ja) | ||
Root et al. | HIV-1 gp41 as a target for viral entry inhibition | |
JP2019172710A5 (ja) | ||
JP2017537893A5 (ja) | ||
US7070787B2 (en) | Method of inducing the production of antibodies to HIV | |
WO2001043779A3 (en) | Anti-hiv-1 conjugates for treatment of hiv disease | |
Ashkenazi et al. | Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides | |
WO2007134037A3 (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
Banerjee et al. | Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice | |
EP4378958A3 (en) | High-affinity anti-mertk antibodies and uses thereof | |
WO2020252393A8 (en) | Compositions and methods for the treatment of human immunodeficiency virus | |
Wang et al. | Inhibition of HIV virus by neutralizing Vhh attached to dual functional liposomes encapsulating dapivirine | |
McGaughey et al. | Progress towards the development of a HIV-1 gp41-directed vaccine | |
CA2794632A1 (en) | Bifunctional molecules for inactivating hiv and blocking hiv entry | |
JP2018516247A5 (ja) | ||
WO2011008863A4 (en) | Stereoisomer peptides and their polymer conjugates for hiv disease | |
US20150011483A1 (en) | Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120 | |
US9114107B2 (en) | Compositions for inhibiting virus entry and promoting virolysis, and methods thereof | |
GB2471692A (en) | HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats | |
CN1327897C (zh) | Hiv感染的肽衍生物融合抑制剂 | |
JP2006503849A5 (ja) | ||
JP2010511706A5 (ja) | ||
Su et al. | Virus Entry Inhibitors: Past, Present, and Future | |
CA2498483A1 (en) | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome | |
CA2073060A1 (en) | Monoclonal antibody specific for non-immunodominant epitope of hiv proteins |